Navigation Links
Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
Date:11/3/2008

SAN DIEGO, Nov. 3 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced that it has initiated a Phase 2 clinical study with MP-376 for use as a maintenance therapy in reducing the incidence of pulmonary exacerbations in patients with chronic obstructive pulmonary disease (COPD). MP-376 is the company's novel formulation of levofloxacin inhalation solution.

The Phase 2, U.S. multi-center randomized, double-blind, placebo-controlled study (Mpex 302) is expected to enroll approximately 300 COPD patients to evaluate the safety, tolerability and efficacy of 5 days of dosing every 28 days, for up to 12 treatment cycles. Inclusion criteria are designed to enroll patients at high risk for acute exacerbations. The primary efficacy endpoint in this study is a comparison of the rate of acute exacerbations in patients treated with MP-376 versus placebo control. Additional endpoints will include the number, duration and severity of acute exacerbations, lung function, quality of life and functional status.

Chronic bacterial infection of the lower airways of patients with COPD results in inflammation that causes lung damage, as well as predisposes patients to acute exacerbations that arise from a variety of causes. Bacterial infections are a leading cause of these exacerbations and antibiotics are widely used to treat exacerbations when they occur. Although several bronchodilators and anti-inflammatory agents have been licensed for maintenance treatment, there are currently no inhaled antibiotics that are cleared for use in the U.S. for preventing the root cause of these exacerbations.

"There is significant enthusiasm in the clinical community for an inhaled antibiotic that can reduce the incidence of acute exacerbations in COPD in high risk patients," stated Dr. Jeff Loutit, Chief Medical Officer of Mpex Pharmaceuticals. "A therapy that addresses the underlying issues associated with COPD to reduce exacerbations would be highly beneficial and pote
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
4. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
5. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
6. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
7. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
8. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2009)...Opinion Recommends Approval of New Anti-TNF Therap...(TM) Autoinjector , , HORSHAM, Pa. and KENILWOR...or Ortho Biotech Inc. and Schering-Plough Corporat...tee for Medicinal Products for Human Use (CHMP) of...sitive opinion recommending the approval of SIMPON...
(Date:6/25/2009)..., N.J., June 25 "Congratulations P...ceutical companies to cut prescription costs for t...Strata Company, Inc. "We thought you should know t... done the same for psoriasis sufferers of all ages...ompany, Inc., and the submission of their findings...
(Date:6/24/2009)...G, Pa., June 25 In a revolutionary...y published in the British Journal of Nutrition (a...at Prebiotics reduce cholesterol and triglycer...y 33%. , , The controlled clinical study was co...otics had an 80% survival rate to 24 months versus...
(Date:6/24/2009)...ry top-line results of second Phase III study show...and improved daily function in fibromyalgia patien...udy , , PALO ALTO, Calif., and BRUSSELS, June 2...ted information -- Jazz Pharmaceuticals, Inc. (Na...nounced today positive preliminary top-line result...
Breaking Medicine Technology:SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10Innovative Psoriasis Treatment PSORENT(R) Announces Healthcare Cost Savings Potential Consistent with President Obama's Announcement on Healthcare Reform 2New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33% 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 6Verax Biomedical Receives 510 28k 29 Clearance from FDA for Platelet PGD Test 688 1Verax Biomedical Receives 510 28k 29 Clearance from FDA for Platelet PGD Test 688 2Verax Biomedical Receives 510 28k 29 Clearance from FDA for Platelet PGD Test 688 3Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C Difficile Bacteria 322 1Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C Difficile Bacteria 322 2Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C Difficile Bacteria 322 3Pregnancy may slow not accelerate progression to AIDS 1581 1Pregnancy may slow not accelerate progression to AIDS 1581 2Pregnancy may slow not accelerate progression to AIDS 1581 3How the brain handles surprise good and bad 458 1How the brain handles surprise good and bad 458 2
... FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2...ounced that Study 103, a,Phase III clinical trial ...Viread(R) (tenofovir disoproxil fumarate or tenofo...c hepatitis B virus,(HBV) infection, met its prima... non-inferior to the company,s once-daily antivira...
... New study demonstrates 75% of patients receiving ...lycemia, CHICAGO, June 25, 2007 /PRNewswire-FirstC...he 67th Scientific Sessions of the,American Diabet...estigational treatment liraglutide, a once- daily ...vo Nordisk for the treatment of,type 2 diabetes si...
Other Medicine Technology:Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:7/3/2009)...r through divorce or death in middle age may tripl...ly 2 (HealthDay News) -- Middle-aged adults who li...r Alzheimer,s disease later in life compared to th...e risk is three times higher among those who are d...edish and Finnish researchers. , The study incl...
(Date:7/3/2009)... Eva,s Village, ( http://www.EvasVillage...ity, Seeks Buyers for 35mm Michael Jackson Film Pr... Paterson, NJ (PRWEB) July 3, 200... a non-profit New Jersey anti-poverty charity, see...rint of Michael Jackson,s "Thriller" mus...
(Date:7/3/2009)... Julian Whitaker, MD, a founder of the a...rt on searchjointpain.com, a new informational Web...onditions and solutions. , ...ker, MD, a founder of the alternative health movem...om, a new informational Web site devoted to all as...
(Date:7/2/2009)...ly 2 Recent news report...dentials and ensuring that physicians meet high st...g to the American Board of Medical Specialties (AB...oards in their efforts to develop and implement ed...ation and certification of physician specialists. ...
Breaking Medicine News(10 mins):Health News:Living Alone Increases Odds of Developing Dementia 2Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 2Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 3Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 4Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 5Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4
...new drug CX717 or amakine that has been developed ...ts on performance could now become a thing of the ...rkers, health // professionals, military personnel...ugh the day and night. The drug effects were studi...
...tal in Chandigarh has been compromising with the l...rupulously through its in-house dispensary says a ...to light // by a news team, which exposed and cap... soon as the accusation was made those involved fi...
...om University of North Carolina at Chapel Hill had... infecting human hair for long. Their study was pu...he American Academy // of Dermatology. Contrary to...iene and social background, anyone can become infe...
...again, it is only tiny gadgets that have changed t...esearchers have developed a small device resemblin...le with balance // disorder, by giving the wearer'...erhaps some day be even used to improve the perfor...
Other Medicine News:Health News:With New Drug To Fight Against Sleeping, Your Increment Is Not Far Away 2Health News:Time For Lice To Go 2
Joseph skin hook is a single end-sharp with 2 prong.
Experience great vision, comfort and durability in a quarterly-replacement lens.
A unique lens system featuring Balanced Progressive Technology for optimum vision quality at every distance.
The proven daily wear spherical soft contact lens.
Medicine Products: